Advanced Medical Solutions Group Regulatory News (AMS)

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Trading Update

Winsford, UK, 18 December 2018: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, today announces an update on trading for the year ending 31 December 2018.

The Group continues to make good progress and the Board expects results to be in line with current market expectations.

Chris Meredith, Chief Executive Officer of AMS, said: "The Group continues to deliver good growth supported by innovative product development and is well positioned for the future."

The Group expects to publish its Preliminary Results for the year to 31 December 2018 in March 2019.

- End -

For further information, please contact:

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of products that include tissue adhesives, sutures, haemostats, internal fixation devices, silver alginates, alginates and foams, which it markets under its brands LiquiBand®, RESORBA®, LiquiBand® Fix8™ and ActivHeal® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 77 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 650 employees. For more information please see www.admedsol.com.